Researchers will then evaluate the safety and effectiveness of the selected dose levels in the next phase of the trial, with participants being randomly selected to receive the vaccine or a placebo.
After a six-month follow-up, children who received a placebo will then have the opportunity to receive the vaccine, the company said.
Pfizer’s vaccine has already been authorised for use in people aged 16 and older, and the company hopes to expand the vaccination age range by early 2022.
Related Posts
Moderna have also begun vaccine trials in children under the age of 12, making the announcement on 16 March.
